Baxter International Inc.  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
72.81
-0.64 (-0.87%)
Apr 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 72.41 - 74.00
52 week 62.80 - 75.68
Open 73.52
Vol / Avg. 4.26M/4.06M
Mkt cap 39.39B
P/E 19.80
Div/yield 0.49/2.69
EPS 3.68
Shares 540.94M
Beta 0.64
Inst. own 83%
Jul 14, 2014
Q2 2014 Baxter International Inc. Earnings Release (Estimated) Add to calendar
May 6, 2014
Baxter International Inc. Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
Apr 17, 2014
Q1 2014 Baxter International Inc. Earnings Release
Apr 17, 2014
Q1 2014 Baxter International Inc. Earnings Conference Call - Webcast
Mar 27, 2014
Baxter International Inc Conference Call to Discuss its Plans to Create Two Separate Leading Global Healthcare Companies - Webcast
Mar 11, 2014
Baxter International Inc. at Barclays Healthcare Conference - Webcast
Mar 3, 2014
Baxter International Inc. at Cowen Health Care Conference - Webcast
Feb 26, 2014
Baxter International Inc. at RBC Capital Markets Healthcare Conference - Webcast
Feb 25, 2014
Baxter International Inc. at Citi Global Healthcare Conference - Webcast
Jan 23, 2014
Q4 2013 Baxter International Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 14.07% 13.19%
Operating margin 18.00% 17.30%
EBITD margin - 27.49%
Return on average assets - 8.70%
Return on average equity - 26.13%
Employees 61,000 -
CDP Score - 82 B

Address

ONE BAXTER PKWY, DF2-1W
DEERFIELD, IL 60015
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Baxter International Inc. (Baxter,) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operated in two segments: BioScience and Medication Delivery. It is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors� offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 27 countries and sells the products in more than 100 countries. In September 2013, Baxter International Inc completed the acquisition of Gambro AB.

Officers and directors

Robert L. Parkinson Jr. Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Robert J. Hombach CPA Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Sebastian J. Bufalino Corporate Vice President, Controller
Age: 52
Bio & Compensation  - Reuters
Todd S. Young Corporate Vice President, Treasurer
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Phillip L. Batchelor Corporate Vice President - Quality and Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters
Jean-Luc Butel Corporate Vice President, President - International
Age: 56
Bio & Compensation  - Reuters
Ludwig N. Hantson Ph.D. Corporate Vice President, President - BioScience
Age: 50
Bio & Compensation  - Reuters
Peter S. Hellman Lead Independent Director
Age: 63
Bio & Compensation  - Reuters